美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Militia Long/Short Equity ETF

38.99

+0.30000.78%

成交量：58.43萬

成交額：2,274.74萬

市值：4.51億

市盈率：- -

高：39.12

開：38.86

低：38.70

收：38.69

52周最高：39.12

52周最低：25.85

股本：1,157.00萬

流通股本：1,113.00萬

量比：1.65

換手率：5.25%

股息：- -

股息率：- -

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

78億美金，跨國藥企達成閃電併購

药圈观察局

澤璟製藥-U事件點評：ZG006授權給艾伯維澤速寧獲批上市

甬兴证券有限公司

5000億！一戰封神，他是中國最成功的美國人

優赫得在華拓展第六個適應症，去年上半年銷售額突破22億美金

德曲妥珠單抗胃癌新適應證獲批，填補臨床治療空白

優赫得®在華獲批治療既往接受過一種含曲妥珠單抗治療方案的局部晚期或轉移性HER2陽性成人胃或胃食管結合部腺癌患者

向「領跑者」跨越！中國雙抗藥物再迎高光時刻

每日经济新闻

Rybrevant雙靶風暴來襲：強生重塑難治性結直腸癌治療天花板，51% ORR+11.3月肝轉移PFS，EGFR/MET雙鎖+免疫殺傷直擊耐藥痛點

医道社创新药新...

ORR高達89.5%！智翔金泰BCMA/CD3雙抗申報上市

全球首個HER2突變肺癌口服靶向藥上新，境外新藥加速入華新政助力藥品一年落地

君賽生物：聚焦實體瘤「免清淋」突破，GC101預計2026年提交上市申請

肺癌一線！「伏美替尼」新適應症擬納入突破性療法

優赫得®在華獲批為首個用於既往在轉移性疾病階段經一種或一種以上內分泌治療進展的HER2低表達或超低表達乳腺癌患者的HER2靶向療法

多個新藥或新適應症獲FDA批准，涉及腫瘤、肥胖、肺纖維化等領域

關注，又新增2款國產創新藥擬納入突破性療法

北京药研汇

君賽生物赴港IPO：核心產品數據平平且專利仍待審批遞表前股東要求回購或轉讓股權

新股前瞻|佈局TCE腫瘤療法千億藍海，時邁藥業能否博得市場青睞？

吉利德Anito-cel 神經毒性低，2年多發性骨髓瘤生存率高 | ASH25

iza-bren食管鱗癌Ⅲ期臨床期中分析迎關鍵突破

每日经济新闻

一哥新高，要起風了

CPHI制药在线

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣0平台費、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣0平台費、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/ORR/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"ORR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","market":"US","secType":"STK","nameCN":"Militia Long/Short Equity ETF","latestPrice":38.99,"timestamp":1772053200000,"preClose":38.69,"halted":0,"volume":584258,"delay":0,"changeRate":0.007753941586973488,"floatShares":11130000,"shares":11570000,"eps":0,"marketStatus":"盤前交易","change":0.3,"latestTime":"02-26 04:16:46 EST","open":38.86,"high":39.12,"low":38.7,"amount":22747422.09717,"amplitude":0.010856,"askPrice":43.2,"askSize":100,"bidPrice":34.98,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1772116200000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":38.99,"sharesOutstanding":11570000,"nav":38.36,"aum":443825200,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":39.49,"preClose":38.99,"latestTime":"19:10 EST","volume":942,"amount":36966.338,"timestamp":1772064629016,"change":0.5,"changeRate":0.012824,"amplitude":0.012824},"volumeRatio":1.6490994331042295,"impliedVol":0.1348,"impliedVolPercentile":0.9118},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","floatShares":11130000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.6490994331042295,"shares":11570000,"dividePrice":0,"high":39.12,"amplitude":0.010856,"preClose":38.69,"low":38.7,"week52Low":25.85,"pbRate":"--","week52High":39.12,"institutionHeld":0,"latestPrice":38.99,"eps":0,"divideRate":0,"volume":584258,"delay":0,"ttmEps":0,"open":38.86,"prevYearClose":34.16,"prevWeekClose":38.73,"prevMonthClose":36.48,"prevQuarterClose":34.16,"fiveDayClose":38.54,"twentyDayClose":35.98,"sixtyDayClose":33.39},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ORR\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ORR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ORR\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ORR\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2613764020","title":"78億美金，跨國藥企達成閃電併購","url":"https://stock-news.laohu8.com/highlight/detail?id=2613764020","media":"药圈观察局","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613764020?lang=zh_tw&edition=fundamental","pubTime":"2026-02-23 20:03","pubTimestamp":1771848202,"startTime":"0","endTime":"0","summary":"2023年6月，因一名患者死亡，FDA暂停了anito-cel的关键II期临床试验。然而，仅两个月后，FDA经审查解除了搁置，试验重回正轨。同年11月，Kite进一步扩大合作，支付2.85亿美元以获得Arcellx另一条管线ACLX-001的权益，并将对Arcellx的股权投资增至2亿美元，持股比例达到约13%。其市值在不到三年内从不足4亿美元飙升至收购前的数十亿美元，堪称“十倍股”。据悉，此次收购的灵魂是Arcellx的两大核心资产。市场方面，多发性骨髓瘤CAR-T市场预计在2030年达到120亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602232009079541ac53&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602232009079541ac53&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1674673428.USD","LU1674673691.USD","LU0965509010.AUD","IE00B19Z3581.USD","LU0882574055.USD","LU1778281490.HKD","LU0289739699.SGD","LU0320765992.SGD","BK4139","IE00BZ1G4Q59.USD","LU1571399168.USD","BK4566","IE00BKVL7J92.USD","LU1057294990.SGD","BK4568","IE00B7SZLL34.SGD","LU0823416689.USD","LU1061106388.HKD","LU0234570918.USD","IE00B19Z3B42.SGD","LU0114720955.EUR","GILD","SG9999015945.SGD","BK4550","LU1037948897.HKD","IE0002270589.USD","LU1066053197.SGD","LU1066051498.USD","LU2089984988.USD","BK4578","IE00B3T34201.USD","IE00BSNM7G36.USD","LU0965509283.SGD","LU2468319806.SGD","LU0965508806.USD","LU0861579265.USD","LU2324357040.USD","LU2087621335.USD","LU0109394709.USD","LU1037948541.HKD","BK4583","ORR","LU0122379950.USD","BK4585","LU0058720904.USD","SG9999015952.SGD","SG9999015986.USD","LU0889565916.HKD","CVR","BK4588"],"gpt_icon":0},{"id":"2606259515","title":"澤璟製藥-U事件點評：ZG006授權給艾伯維 澤速寧獲批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2606259515","media":"甬兴证券有限公司","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606259515?lang=zh_tw&edition=fundamental","pubTime":"2026-01-25 09:40","pubTimestamp":1769305230,"startTime":"0","endTime":"0","summary":"2025 年 11 月，ZG006 单药治疗晚期NEC 获 CDE 纳入突破性治疗品种公示名单，有望通过附条件批准实现早日上市。此外ZG006 联合 PD-1/PD-L1 抑制剂及化疗用于小细胞肺癌的临床试验已获批。吉卡昔替尼新入医保、泽速宁获批上市吉卡昔替尼作为首个获批国产治疗骨髓纤维化的 JAK 抑制剂成功纳入医保。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260125094033a4529cab&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260125094033a4529cab&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0310799852.SGD","LU0689472784.USD","LU0289961442.SGD","LU2089283258.USD","LU0795875086.SGD","LU1934455194.USD","LU1496350502.SGD","LU1244550577.SGD","LU1003077747.HKD","LU2237443382.USD","SG9999015986.USD","IE0002270589.USD","LU1732800096.USD","LU0122379950.USD","IE00BN8TJ469.HKD","ABBV","LU2237443978.SGD","LU1057294990.SGD","LU1929549753.HKD","LU0965508806.USD","LU0310800379.SGD","LU0949170772.SGD","IE00BVYPNW00.USD","LU1037948541.HKD","SG9999015978.USD","LU0234572021.USD","LU1496350171.SGD","IE0009355771.USD","LU1023059063.AUD","LU2087621335.USD","IE00BFTCPJ56.SGD","LU2112291526.USD","ORR","IE00BJJMRZ35.SGD","LU0545039389.USD","IE0002141913.USD","LU1551013342.USD","IE00BJT1NW94.SGD","LU1983299246.USD","LU2133065610.SGD","LU0256863811.USD","LU1291159041.SGD","LU0069063385.USD","BK4550","LU2468319806.SGD","LU1989772923.USD","BK4533","LU1093756325.SGD","SG9999011175.SGD","LU0912757837.SGD"],"gpt_icon":0},{"id":"2606125812","title":"5000億！一戰封神，他是中國最成功的美國人","url":"https://stock-news.laohu8.com/highlight/detail?id=2606125812","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606125812?lang=zh_tw&edition=fundamental","pubTime":"2026-01-25 08:34","pubTimestamp":1769301264,"startTime":"0","endTime":"0","summary":"文 | 华商韬略 韩翔州2010年，旧金山的一次私人聚会上，已在中国创业有成的美国人欧雷强，结识了已在美国功成名就的中国人王晓东。终于在年底，他们决定一起冒险：在中国建立一家世界级的生物科技公司，在中国做创新药卖给全世界。作为一名连续创业者，欧雷强的履历堪称完美。事实证明，中国没有辜负欧雷强的眼光。欧雷强预见到，中国的监管环境即将迎来一场有利于创新药的剧变。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1769137313695679325","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["LU1719994722.HKD","BK4195","ASH","ORR","LU1969619763.USD","LU1251922891.USD","LU0588546209.SGD","BK1161","BK1583","06160","LU1770034418.SGD","LU2463526074.USD","LU1303224171.USD","BK1500","BMS","BK1588","LU2328871848.SGD","PFS","LU0307460666.USD","BK4211","BK4109"],"gpt_icon":0},{"id":"2605034473","title":"優赫得在華拓展第六個適應症，去年上半年銷售額突破22億美金","url":"https://stock-news.laohu8.com/highlight/detail?id=2605034473","media":"蓝鲸财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605034473?lang=zh_tw&edition=fundamental","pubTime":"2026-01-23 17:13","pubTimestamp":1769159628,"startTime":"0","endTime":"0","summary":"2024 年全球已获批上市的 17 款 ADC 药物合计销售额达百亿美金，其中第一三共的德曲妥珠单抗表现尤为突出，2024 年销售额达到 34.8 亿美元、同比增长 52%。根据阿斯利康2025年上半年财报，其自身销售额为12.6亿美元，增长38%；包括合作伙伴第一三共报告的销售额在内，总销售额为22.9亿美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1769159310955231385","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["OS","BK4080","BK4231","PFS","BK4195","ADC","ORR","BK4211","BK4097"],"gpt_icon":0},{"id":"2605989254","title":"德曲妥珠單抗胃癌新適應證獲批，填補臨床治療空白","url":"https://stock-news.laohu8.com/highlight/detail?id=2605989254","media":"上观新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605989254?lang=zh_tw&edition=fundamental","pubTime":"2026-01-22 19:18","pubTimestamp":1769080687,"startTime":"0","endTime":"0","summary":"由阿斯利康和第一三共共同开发与商业化的优赫得（英文商品名：Enhertu，通用名：注射用德曲妥珠单抗）今天获中国国家药品监督管理局（NMPA）批准，本品单药适用于治疗既往接受过一种含曲妥珠单抗治疗方案的局部晚期或转移性HER2阳性成人胃或胃食管结合部腺癌患者。德曲妥珠单抗是由阿斯利康和第一三共联合开发和商业化的一款独特设计靶向HER2的抗体偶联药物（ADC）。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601223627553572.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["OS","BK4195","BK4231","BK4080","ORR","BK4211","PFS","ADC","BK4097"],"gpt_icon":0},{"id":"2605495703","title":"優赫得®在華獲批治療既往接受過一種含曲妥珠單抗治療方案的局部晚期或轉移性HER2陽性成人胃或胃食管結合部腺癌患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2605495703","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605495703?lang=zh_tw&edition=fundamental","pubTime":"2026-01-22 18:38","pubTimestamp":1769078280,"startTime":"0","endTime":"0","summary":"研究显示，对于局部晚期或转移性HER2阳性成人胃或胃食管结合部腺癌患者，与雷莫西尤单抗+紫杉醇相比，德曲妥珠单抗带来具有显著统计学差异和临床意义的总生存期改善。自一年多前首次在中国获批用于HER2阳性局部晚期或转移性胃癌以来，德曲妥珠单抗仅可用于三线及后线治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4868984_ZH68984_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU2506951958.HKD","ADC","LU2247934214.USD","BK4195","SG9999015978.USD","LU2237443622.USD","IE00BFMHRM44.USD","LU1571399168.USD","LU1046421795.USD","ORR","CSCO","LU0234572021.USD","LU2462157665.USD","IE00BKVL7J92.USD","SG9999001440.SGD","BK4579","LU2506952097.USD","LU2417539215.USD","SG9999015945.SGD","BK4080","BK4588","LU2237443549.SGD","LU0109394709.USD","LU1244550577.SGD","LU2237443895.HKD","OS","BK4585","LU1221951129.SGD","LU1244550494.USD","LU1196500208.SGD","LU1929549753.HKD","LU0868494617.USD","LU1894683348.USD","PFS","LU1066051498.USD","BK4231","IE000M9KFDE8.USD","LU0320765992.SGD","LU1880398471.USD","LU1880398554.USD","BK4560","AZN","BK4527","LU0792757196.USD","BK4612","LU1066053197.SGD","LU1221951046.USD","LU2506951875.HKD","BK4097","LU2237443382.USD"],"gpt_icon":0},{"id":"2603130816","title":"向「領跑者」跨越！ 中國雙抗藥物再迎高光時刻","url":"https://stock-news.laohu8.com/highlight/detail?id=2603130816","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603130816?lang=zh_tw&edition=fundamental","pubTime":"2026-01-14 20:14","pubTimestamp":1768392877,"startTime":"0","endTime":"0","summary":"2026年1月12日，第四十四届摩根大通医疗健康大会在美国旧金山召开，当全球生物医药界的目光聚焦于该会议时，大洋彼岸的中国接连传来重磅消息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601143619177920.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601143619177920.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1583","BK4107","BK4007","LU2476274720.SGD","BK4195","BK4211","LU0348766576.USD","LU2487616109.SGD","LU1829250122.USD","LU0053666078.USD","LU0210528500.USD","09995","BK4588","LU0348784397.USD","LU0348827113.USD","IE00B543WZ88.USD","LU0348767384.USD","LU0417516902.SGD","GSK.UK","PFS","BK1161","LU1961090484.USD","GSK","ORR","LU2328871848.SGD","BK1574","LU2399975544.HKD","LU1720050803.USD","L","LU0561508036.HKD","LU0417516738.SGD","IE00B5MMRT66.SGD","LU0634319403.HKD","LU1794554557.SGD","BK4532","LU2476274308.USD","LU1969619763.USD","IE00BPRC5H50.USD","LU2488822045.USD","BMS","BK4585","LU0348735423.USD","09926","LU0540923850.HKD","LU0348783233.USD","LU0348825331.USD","LU0417516571.SGD","LU2778985437.USD"],"gpt_icon":0},{"id":"2603985636","title":"Rybrevant雙靶風暴來襲：強生重塑難治性結直腸癌治療天花板，51% ORR+11.3月肝轉移PFS，EGFR/MET雙鎖+免疫殺傷直擊耐藥痛點","url":"https://stock-news.laohu8.com/highlight/detail?id=2603985636","media":"医道社创新药新...","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603985636?lang=zh_tw&edition=fundamental","pubTime":"2026-01-13 20:22","pubTimestamp":1768306935,"startTime":"0","endTime":"0","summary":"可Rybrevant联合化疗，在OrigAMI-1研究中直接打出51%总体ORR、一线亚组73%、肝转移PFS 11.3个月！Rybrevant单药ORR 22%，PFS 3.7个月；联合化疗ORR 43%，PFS 7.4个月，DCR 86%。传统单抗易逃逸，Rybrevant加持Fc介导ADCC/ADCP，激活NK/巨噬细胞“围剿”癌细胞。ctDNA研究证实，停药后耐药克隆消退，Rybrevant清除残留，恢复敏感性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260113220712a7162b63&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260113220712a7162b63&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BJJMRZ35.SGD","LU0640476718.USD","LU1061106388.HKD","IE0009355771.USD","LU2505996681.GBP","LU2347655156.SGD","IE0002141913.USD","LU1066051811.HKD","LU1989771016.USD","IE00B42XCP33.USD","IE00BLSP4239.USD","LU1506573853.SGD","LU0889566641.SGD","IE00BZ1G4Q59.USD","PFS","BK4534","LU2750360997.AUD","LU2471134879.HKD","LU2471134952.CNY","LU0058720904.USD","LU1430594728.SGD","LU1732800096.USD","LU0124676726.USD","LU0787776722.HKD","IE00BFTCPJ56.SGD","LU0795875169.SGD","LU1059921491.USD","IE0034235303.USD","LU0070217475.USD","LU1221951046.USD","MET","IE00B19Z3B42.SGD","LU2430703251.USD","JNJ","LU0234570918.USD","LU1291159041.SGD","LU1244550221.USD","LU2471134523.USD","LU0795875086.SGD","BK4162","IE00BLSP4452.SGD","LU1894683348.USD","LU0683600562.USD","BK4195","BK4007","LU1989772840.SGD","ORR","BK4550","SG9999001440.SGD","LU0320765646.SGD"],"gpt_icon":0},{"id":"2601490365","title":"ORR高達89.5%！智翔金泰BCMA/CD3雙抗申報上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2601490365","media":"医药魔方","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601490365?lang=zh_tw&edition=fundamental","pubTime":"2026-01-08 19:01","pubTimestamp":1767870060,"startTime":"0","endTime":"0","summary":"1月8日，智翔金泰宣布双抗药物GR1803的附条件上市申请已获得国家药监局受理，用于治疗既往至少接受过三线治疗的复发或难治性多发性骨髓瘤成人患者。GR1803是智翔金泰自主研发的一款BCMA/CD3双抗药物，其结合BCMA的亲和力较结合CD3的亲和力高两个数量级。2025年11月，智翔金泰在ASH 2025年会上公布了GR1803治疗R/R MM的I期研究数据。结果显示，在至少接受了一次疗效评估的57例患者中，客观缓解率为89.5%。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-01-08/doc-inhfqyhi5239845.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688443","ORR","BK0239"],"gpt_icon":0},{"id":"2601861815","title":"全球首個HER2突變肺癌口服靶向藥上新，境外新藥加速入華新政助力藥品一年落地","url":"https://stock-news.laohu8.com/highlight/detail?id=2601861815","media":"蓝鲸财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601861815?lang=zh_tw&edition=fundamental","pubTime":"2026-01-06 15:01","pubTimestamp":1767682912,"startTime":"0","endTime":"0","summary":"据悉，该药为全球首个且目前唯一在中国获批治疗HER2突变晚期非小细胞肺癌的口服靶向药物。2026年1月6日，首批药品正式装车发往全国，为患者用药提供有力保障。肺癌是中国发病率和死亡率最高的恶性肿瘤之一。其中，HER2突变患者的比例约4%。过去，HER2突变肺癌患者一直面临着治疗选择有限、生存获益不理想的困境。此外，宗艾替尼的安全性可控，研究中治疗停药率仅2.9%。肺癌是最容易发生脑转移的癌症之一。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1767682845418079324","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK4211","ORR","BK4195","PFS"],"gpt_icon":0},{"id":"2595412750","title":"君賽生物：聚焦實體瘤「免清淋」突破，GC101預計2026年提交上市申請","url":"https://stock-news.laohu8.com/highlight/detail?id=2595412750","media":"新浪科技","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595412750?lang=zh_tw&edition=fundamental","pubTime":"2025-12-30 10:41","pubTimestamp":1767062460,"startTime":"0","endTime":"0","summary":"新浪科技讯 12月30日上午消息，日前，聚焦实体瘤创新细胞疗法与创新药开发的上海君赛生物股份有限公司 正式向港交所递交招股书，拟依据港股18A章登陆生物科技板块。　　目前，GC101用于治疗黑色素瘤的临床试验正在开展关键II期临床试验，预计将于2026年提交生物制品许可申请；GC101用于治疗非小细胞肺癌的临床管线目前处于Ib期临床。　　按照计划，GC101预计2026年提交上市申请，若成功获批，将成为国内首个上市的TIL疗法。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/newstock/2025-12-30/doc-inhepszw4394800.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["TIL","BK4505","ORR","BK4139"],"gpt_icon":0},{"id":"2594965422","title":"肺癌一線！「伏美替尼」新適應症擬納入突破性療法","url":"https://stock-news.laohu8.com/highlight/detail?id=2594965422","media":"新浪医药","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2594965422?lang=zh_tw&edition=fundamental","pubTime":"2025-12-26 19:30","pubTimestamp":1766748600,"startTime":"0","endTime":"0","summary":"12 月 25 日，CDE 官网显示，艾力斯医药伏美替尼的一项新适应症拟纳入突破性治疗品种，适应症为用于具有 EGFR PACC 突变的局部晚期或转移性非小细胞肺癌成人患者的一线治疗。今年 7 月，伏美替尼的第 3 项适应症上市申请获得 CDE 受理，并被纳入优先审评，用于既往经含铂化疗治疗时或治疗后出现疾病进展或不耐受含铂化疗并且存在EGFR 20 外显子插入突变的局部晚期或转移性 NSCLC 成人患者的治疗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-26/doc-inhecrxf2583740.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4211","PFS","ORR","BK4195"],"gpt_icon":0},{"id":"2594360732","title":"優赫得®在華獲批為首個用於既往在轉移性疾病階段經一種或一種以上內分泌治療進展的HER2低表達或超低表達乳腺癌患者的HER2靶向療法","url":"https://stock-news.laohu8.com/highlight/detail?id=2594360732","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2594360732?lang=zh_tw&edition=fundamental","pubTime":"2025-12-25 15:30","pubTimestamp":1766647800,"startTime":"0","endTime":"0","summary":"在对HER2超低表达患者进行的探索性分析中，显示HER2超低表达患者群体的试验结果和HER2低表达试验群体的结果具有一致性。经筛查，约85%的HR阳性、HER2阴性转移性乳腺癌患者被检测出有HER2低表达或HER2超低表达3。目前，对于HR阳性转移性乳腺癌患者，不论HER2表达水平如何，内分泌治疗仍被广泛用于早期治疗方案。基于德曲妥珠单抗已取得的临床实践改变，此次获批将为更广泛的HER2表达转移性乳腺癌患者带来亟需的靶向治疗选择。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4853703_ZH53703_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4195","BK4231","LU0889565916.HKD","LU2456880835.USD","IHC","AZN","BK4211","BK4007","LU2236285917.USD","LU0109394709.USD","BK4225","BK4080","LU1829250122.USD","LU0320765992.SGD","HR","BK4585","LU2417539215.USD","PFS","BK4203","BK4588","LU2462157665.USD","BK4162","ADC","ORR","BK4568"],"gpt_icon":0},{"id":"2593176440","title":"多個新藥或新適應症獲FDA批准，涉及腫瘤、肥胖、肺纖維化等領域","url":"https://stock-news.laohu8.com/highlight/detail?id=2593176440","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593176440?lang=zh_tw&edition=fundamental","pubTime":"2025-12-24 09:16","pubTimestamp":1766538973,"startTime":"0","endTime":"0","summary":"近日，多个创新药或新适应症获美国食品药品监督管理局批准，涉及罗氏、诺和诺德、勃林格殷格翰等。这些新药覆盖肿瘤、肥胖、肺纤维化等多个治疗领域，为患者带来了新的治疗选择。此次FDA批准基于关键性3期FIBRONEER-ILD临床试验结果，数据显示Jascayd可有效减缓PPF患者的肺功能下降。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224091748a6c7f4a2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224091748a6c7f4a2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ORR","BK4161","CR","NVO"],"gpt_icon":0},{"id":"2592987199","title":"關注，又新增2款國產創新藥擬納入突破性療法","url":"https://stock-news.laohu8.com/highlight/detail?id=2592987199","media":"北京药研汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592987199?lang=zh_tw&edition=fundamental","pubTime":"2025-12-19 08:01","pubTimestamp":1766102465,"startTime":"0","endTime":"0","summary":"此次该药物拟纳入突破性疗法也证明了其再次被认可。另外，宁波新湾科技本次拟纳入突破性疗法的产品为NB003片，本品单药用于既往接受过二线标准治疗的胃肠道间质瘤。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219080408a45d5c7b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219080408a45d5c7b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","LU2417539215.USD","LU0109394709.USD","AZN","BK4568","LU2456880835.USD","LU0889565916.HKD","BK4007","LU0320765992.SGD","LU1829250122.USD","LU1223082196.USD","CDE","BK4017","LU2462157665.USD","LU2236285917.USD","BK4588","LU1223082519.USD","LU1223083913.SGD","ORR"],"gpt_icon":0},{"id":"2592502964","title":"君賽生物赴港IPO：核心產品數據平平且專利仍待審批 遞表前股東要求回購或轉讓股權","url":"https://stock-news.laohu8.com/highlight/detail?id=2592502964","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592502964?lang=zh_tw&edition=fundamental","pubTime":"2025-12-17 15:10","pubTimestamp":1765955400,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！　　近日，上海君赛生物股份有限公司正式向港交所递交招股说明书。招股书显示，公司专注于实体瘤创新细胞疗法的生物科技公司，其核心产品GC101为全球首款无需高强度清淋化疗及IL-2给药的肿瘤浸润淋巴细胞疗法，承载着成为国内首个获批TIL疗法的期望。　　TIL细胞疗法是指通过离体激活来源于肿瘤组织内部的TIL细胞、规模扩增并注入患者体内发挥疗效。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2025-12-17/doc-inhcavhm7560592.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4505","PFS","BK4195","LU0210528500.USD","LU2487616109.SGD","ORR","BK4107","TIL","BK4585","L","LU0053666078.USD","BK4211","BK4588","BK4139"],"gpt_icon":0},{"id":"2590394122","title":"新股前瞻|佈局TCE腫瘤療法千億藍海，時邁藥業能否博得市場青睞？","url":"https://stock-news.laohu8.com/highlight/detail?id=2590394122","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590394122?lang=zh_tw&edition=fundamental","pubTime":"2025-12-09 13:05","pubTimestamp":1765256702,"startTime":"0","endTime":"0","summary":"近日，又一创新药企正式向港交所提交上市申请。在此背景下，作为一家专注于实体瘤TCE疗法、且具备多款全球前列临床管线的企业，时迈药业的上市进程亦自然备受瞩目。布局TCE疗法 四款创新药物处于临床阶段智通财经APP了解到，时迈药业目前仍处于临床研发阶段，并无产品商业化。根据时迈药业招股书披露，当前仅有两款用于实体瘤的TCE药物获得全球批准，市场存在大量空白，这为具备相关布局能力的创新药企提供了结构性机遇。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1379203.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0210528500.USD","BK4187","BK4588","BK4585","LU2487616109.SGD","LU0053666078.USD","IE0031619046.USD","BK4231","IE00B7SZL793.SGD","BK4006","BK4107","ORR","BK4080","ADC","CRS","IE00B19Z4B17.USD","LU0963586101.USD","IE00B66KJ199.SGD","L","LU2065731478.USD"],"gpt_icon":0},{"id":"2590451393","title":"吉利德Anito-cel 神經毒性低，2年多發性骨髓瘤生存率高 | ASH25","url":"https://stock-news.laohu8.com/highlight/detail?id=2590451393","media":"Minhua笔记","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590451393?lang=zh_tw&edition=fundamental","pubTime":"2025-12-08 11:58","pubTimestamp":1765166299,"startTime":"0","endTime":"0","summary":"在ASH 2025年会上，吉利德旗下Kite Pharma公布Anito-cel在iMMagine-1 II期试验中的更新数据，该靶向BCMA的CAR-T疗法在复发/难治性多发性骨髓瘤患者中显示96% ORR、74% sCR/CR率、95% MRD阴性率，中位随访15.9个月，缓解持续。III期iMMagine-3试验正在招募中，该研究将Anito-cel与标准治疗比较，预计2026年获得数据；该药物获FDA快速通道、孤儿药和RMAT资格。ICANS 发生率为 8%，其中 1 例为 3 级；其余均为 2 级或更低。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208144817a43ac231&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208144817a43ac231&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ASH","CR","CRS","GILD","LU1585245621.USD","LU0109394709.USD","ORR","IE0002270589.USD","SG9999015986.USD","BK4566","LU1430594728.SGD","BK4195","BK4187","SG9999015952.SGD","BK4532","IE00B3T34201.USD","LU1778281490.HKD","LU1571399168.USD","LU0882574055.USD","BK4097","LU0320765992.SGD","BK4568","IE00BZ1G4Q59.USD","LU1839511570.USD","LU0289739699.SGD","LU1066051498.USD","IE00B66KJ199.SGD","LU0234570918.USD","BK4578","IE00B7SZL793.SGD","IE00B19Z4B17.USD","SG9999015945.SGD","BK4585","PFS","OS","LU0889565916.HKD","BK4109","IE00B19Z3581.USD","LU0823416689.USD","BK4139","IE00B7SZLL34.SGD","KOL","IE00BKVL7J92.USD","BK4588","BK4550","IE00B19Z3B42.SGD","LU1674673428.USD","LU1674673691.USD","SG9999015978.USD"],"gpt_icon":0},{"id":"2584941686","title":"iza-bren食管鱗癌Ⅲ期臨床期中分析迎關鍵突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2584941686","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584941686?lang=zh_tw&edition=fundamental","pubTime":"2025-11-19 21:09","pubTimestamp":1763557767,"startTime":"0","endTime":"0","summary":"在创新药研发的竞技场上，Ⅲ期临床的“期中大考”是检验药物价值的试金石。11月18日，百利天恒（SH688506，股价369.30元，市值1525.00亿元）宣布其核心产品——全球首创的EGFR×HER3双抗ADC（抗体药物偶联物）药物izabren，在晚期食管鳞癌Ⅲ期临床试验的预设期中分析中，同时达到无进展生存期和总生存期双主要终点。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202511193569015549.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511193569015549.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["91194","ORR","BK4097","OS","BK4211","BK4195","02615","PFS"],"gpt_icon":0},{"id":"2583441513","title":"一哥新高，要起風了","url":"https://stock-news.laohu8.com/highlight/detail?id=2583441513","media":"CPHI制药在线","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583441513?lang=zh_tw&edition=fundamental","pubTime":"2025-11-13 18:03","pubTimestamp":1763028209,"startTime":"0","endTime":"0","summary":"关注并星标CPHI制药在线百济神州三季报交上了一份高分的答卷，2025年第三季度，百济神州实现营收14.12亿美元，同比去年第三季度增长41%；2025年前三季度，百济神州实现营收38.45亿美元，同比去年前三季度增长43%。最近一次获批是在2024年3月7日，批准治疗复发或难治性滤泡性细胞瘤。百济神州目前的战略是三位一体，用泽布替尼，Bcl-2抑制剂索托克拉以及BTK为靶点的PROTAC药物，来维持其在CLL适应症乃至整个血液疾病适应症的地位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251113191029a6f6e18c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251113191029a6f6e18c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1917777945.USD","LU0069063385.USD","BK4526","ORR","LU2240825500.USD","LU0472753341.HKD","LU2023250504.SGD","LU2229751404.USD","LU2413666699.HKD","LU2106854487.HKD","MTD","LU1974910355.USD","LU1712237335.SGD","LU0124676726.USD","LU0289739343.SGD","LU0289960550.SGD","LU0057025933.USD","LU0511384066.AUD","LU2463526074.USD","LU1923621640.USD","LU1093756168.USD","LU2089279066.USD","06160","IE00BFXG0V08.USD","LU2298064838.USD","LU2125910336.SGD","LU2413666426.HKD","LU0175139822.USD","LU2238339852.HKD","IE00BYQQ9H92.USD","LU1623119135.USD","LU0689626769.HKD","LU0289961442.SGD","ONC","LU1430594728.SGD","LU2355687059.USD","LU2211814178.USD","BK4534","LU2125910179.SGD","LU0347712357.USD","LU2211817866.USD","LU2041044095.USD","BK4121","LU2362540622.SGD","BK4139","BK4588","WM","BK4120","BK4566","LU1585245621.USD","LU1093756325.SGD"],"gpt_icon":1}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":30,"code":"91000000","status":"200"}]}}